In-Depth Insights into the Patient Derived Xenograft (PDX) Models Market: Growth, Trends, and Opportunities for 2025-2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the patient derived xenograft (pdx) models market grown over the years?
The market size for patient-derived xenograft (PDX) models has seen a considerable expansion in recent times. The market is set to escalate from $0.4 billion in 2024 to $0.47 billion in 2025, marking a compound annual growth rate (CAGR) of 16.4%. This growth during the historic period can be credited to factors such as investment in research & development, regulatory backing, formation of partnerships and collaborations, the increasing presence of contract research organizations (CROs), and a surge in cancer incidences.
What Is the forecasted market size and growth rate for the patient derived xenograft (pdx) models market?
The market size of patient derived xenograft (PDX) models is predicted to experience a rapid escalation in the upcoming years, reaching $0.85 billion by 2029 with a compound annual growth rate (CAGR) of 16.0%. This expansion in the forecast period is linked to the increasing need for personalized medicine, surges in the demand for humanized PDX models, a rising prevalence of cancer, emphasis on precision oncology, and a rise in expenditure on cancer research. The forecasted period will witness significant trends such as technological advancements, a surge in demand for humanized PDX models, partnership research initiatives, increasing funding in cancer research, and an intensified focus on immuno-oncology.
Get your patient derived xenograft (pdx) models market report here!
What are the major factors driving growth in the patient derived xenograft (pdx) models market?
The growth of the patient-derived xenograft (PDX) models market is anticipated to be fueled by the increasing demand for personalized medicine. This type of medicine customizes treatments according to the unique characteristics, environment, lifestyle, and genetics of each patient. Due to advancements in genomic research, personalized medicine is gaining popularity as it offers treatments adapted to individual genetic profiles, resulting in more efficient and targeted health solutions. Patient-derived xenograft (PDX) models contribute to personalized medicine by enabling the analysis of individual patient tumors to anticipate treatment responses and adapt therapies. For example, the Personalized Medicine Coalition (PMC), a nonprofit organization based in the US, reported in February 2024 that 16 new personalized treatments for rare diseases were approved by the FDA in 2023, a major upturn from the six approvals in 2022. Consequently, the patient-derived xenograft (PDX) models market is being propelled by the escalating demand for personalized medicine.
What key areas define the segmentation of the global patient derived xenograft (pdx) models Market?
The patient derived xenograft (PDX) models market covered in this report is segmented –
1) By Type: Mice Models, Rat Models
2) By Technique: Heterotopic Implantation, Orthotropic Implantation
3) By Tumor Type: Gastrointestinal Tumor Models, Lung Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Other Tumor Models
4) By Application: Preclinical Drug Development, Precision Medicine, Co-Clinical Trials, Basic Cancer Research
5) By End-User: Academic And Research Organizations, Contract Research Organizations, Pharmaceutical And Biotechnological Companies, Other End-Users
Subsegments:
1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice), Humanized Mice Models, Genetically Modified Mice Models
2) By Rat Models: Immunodeficient Rat Models, Humanized Rat Models, Genetically Modified Rat Models
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17226&type=smp
What are the top market players propelling the growth of the patient derived xenograft (pdx) models industry?
Major companies operating in the patient derived xenograft (PDX) models market are Laboratory Corporation of America Holdings, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., The Jackson Laboratory, Inotiv Inc, Biocytogen Pharmaceuticals Co. Ltd., Taconic Biosciences Inc, BioDuro-Sundia Inc, Horizon Discovery Ltd., Crown Bioscience Inc., Champions Oncology Inc., Oncodesign Services S.A, Genesis Biotechnology Group LLC., Creative Animodel, Abnova Corp., Certis Oncology Solutions Inc., Xentech, Aragen Bioscience Inc., EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH., Urosphere, Hera BioLabs, InnoSer, Pharmatest Services Ltd., IVRS AB, Altogen Inc
How are evolving market trends shaping patient derived xenograft (pdx) models Strategies?
Key players in the patient-derived xenograft (PDX) models market are introducing novel models armed with in vivo bioluminescence imaging features, allowing real-time tracking of tumor progression. The incorporation of in vivo bioluminescence imaging in PDX models boosts the quality of preclinical research in pharmaceutical development as it provides a non-invasive method for continual observation of tumor metastasis and therapeutic responses. In March 2024, InVitro Research Solutions Private Limited, a Contract Research Organization (CRO) based in India, unveiled an inventive orthotopic model of human glioblastoma in NSG-SGM3 mice. This model, utilizing patient-derived xenografts (PDX) and in vivo bioluminescence imaging, is targeted at delivering personalized therapies for glioblastoma, the most prevalent and invasive form of brain cancer. These models are crucial for expanding the knowledge of glioblastoma biology and for testing new targeted treatments and immunotherapies to better patient outcomes.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17226
What regions are dominating the patient derived xenograft (pdx) models market growth?
North America was the largest region in the patient derived xenograft (PDX) models market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (PDX) models market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Patient Portal Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/patient-portal-global-market-report
Patient Positioning Systems Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/patient-positioning-systems-global-market-report
Patient Transport Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/patient-transport-services-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
